January 22, 2025 03:14 PM ESTUpdated 03:46 PM

J&J reinforces Caplyta blockbuster projections, won't shelve neuro prospects

Max Bayer

Pharma Reporter

Johnson & Johnson made the largest splash at this year’s JP Morgan Healthcare Conference, acquiring Intra-Cellular Therapies and its neuropsychiatric drug Caplyta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J reinforces Caplyta blockbuster projections, won't shelve neuro prospects

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Updated: Biogen makes cuts across its research unit, shifting focus to ‘external opportunities’

Chinese startup begins first trial of in vivo CRISPR therapy for blood disease

'No miracles': What Regeneron's George Yancopoulos really thinks of AI

RFK Jr. says he’ll divest interests in CRISPR Therapeutics if confirmed for HHS chief

GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

J&J re­in­forces Caply­ta block­buster pro­jec­tions, won't shelve neu­ro prospects

Pharma Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

J&J reinforces Caplyta blockbuster projections, won't shelve neuro prospects